



FOR IMMEDIATE RELEASE:

Meg Heim
T: 651-558-9939
F: 651-762-4014
MHeim@BioMedix.com
www.BioMedix.com

BioMedix Announces Collaboration with NIH Sponsored Claudication Trial - CLEVER

St. Paul, MN, June 18th, 2009 — Recognizing the importance of comparative effectiveness research in vascular medicine, and its impact on improving the health of patients with Peripheral Arterial Disease (P.A.D.), BioMedix Vascular Solutions has elected to join forces with the CLEVER (Claudication: Exercise versus Endoluminal Revascularization) trial investigators to increase patient recruitment into this pivotal study. BioMedix is a diagnostic company that provides an integrated suite of hardware, software and online services designed to diagnose Peripheral Arterial Disease (P.A.D.). Primary Care Physicians (PCPs) and Podiatrists use the PADnet network to provide a diagnosis and recommendation for the PCP or Podiatrist and their patients.

The CLEVER study is a multi-center clinical trial designed to determine prospectively the optimal treatment for individuals with proximal intermittent claudication due to the aortoiliac arterial insufficiency. It is sponsored by the National Institutes of Health, through the National Heart, Lung and Blood Institute, and is taking place in approximately 30 medical centers across the country. It is the only study of its kind to compare the benefits of supervised exercise, endovascular revascularization, as well as "optimal medical care" (the most common care, which includes claudication pharmacotherapy) in a multi-center prospective randomized trial design.

As a part of BioMedix's new initiative to facilitate vascular research activities to further support its mission to promote early detection and best medical care for persons with P.A.D., BioMedix has offered to inform the Primary Care Physicians (PCPs) in its network about the CLEVER trial and the location of the CLEVER sites nearest to their clinics. BioMedix will provide PCPs with the CLEVER eligibility criteria, and will facilitate the local collaboration among the PCPs and the CLEVER site principal investigators and staff to increase patient recruitment into the study.

For more info on the clever trial, potential patients and referring physicians should contact Dr. Cerezo at icerezo@lifespan.org or call 401-444-1739.

About BioMedix

BioMedix Vascular Solutions, Inc. provides the only integrated suite of hardware, software and online services designed to cost-effectively detect Peripheral Arterial Disease (P.A.D.) and Chronic Venous Insufficiency (CVI). Vascular Specialists, Primary Care Providers, hospitals and health systems use our products to identify these patients. Our devices and software reduce mistakes, provide data for sound analysis, build practice revenue and streamlines reimbursement while providing a platform that supports the continuum of care and increased quality outcomes. For more information, call (877) 854-0014 or log on to www.BioMedix.com.



###